665 related articles for article (PubMed ID: 24831822)
41. Systematic review of the cost-effectiveness of varenicline vs. bupropion for smoking cessation.
Mahmoudi M; Coleman CI; Sobieraj DM
Int J Clin Pract; 2012 Feb; 66(2):171-82. PubMed ID: 22257042
[TBL] [Abstract][Full Text] [Related]
42. An update on therapeutics for tobacco dependence.
Lancaster T; Stead L; Cahill K
Expert Opin Pharmacother; 2008 Jan; 9(1):15-22. PubMed ID: 18076335
[TBL] [Abstract][Full Text] [Related]
43. The efficacy and acceptability of pharmacological monotherapies and e-cigarette on smoking cessation: a systemic review and network meta-analysis.
Meng Y; Xiang S; Qu L; Li Y
Front Public Health; 2024; 12():1361186. PubMed ID: 38841681
[TBL] [Abstract][Full Text] [Related]
44. Interventions to increase adherence to medications for tobacco dependence.
Hollands GJ; Naughton F; Farley A; Lindson N; Aveyard P
Cochrane Database Syst Rev; 2019 Aug; 8(8):CD009164. PubMed ID: 31425618
[TBL] [Abstract][Full Text] [Related]
45. Smoking cessation efficacy and safety of varenicline, an alpha4beta2 nicotinic receptor partial agonist.
Tonstad S
J Cardiovasc Nurs; 2006; 21(6):433-6. PubMed ID: 17293731
[TBL] [Abstract][Full Text] [Related]
46. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers.
Nakamura M; Oshima A; Fujimoto Y; Maruyama N; Ishibashi T; Reeves KR
Clin Ther; 2007 Jun; 29(6):1040-56. PubMed ID: 17692720
[TBL] [Abstract][Full Text] [Related]
47. [Effectiveness and safety of varenicline for smoking cessation].
Christalla P; Dewenter M; El-Armouche A
Dtsch Med Wochenschr; 2012 May; 137(18):940-4. PubMed ID: 22492478
[TBL] [Abstract][Full Text] [Related]
48. Pharmacological interventions for smoking cessation among people with schizophrenia spectrum disorders: a systematic review, meta-analysis, and network meta-analysis.
Siskind DJ; Wu BT; Wong TT; Firth J; Kisely S
Lancet Psychiatry; 2020 Sep; 7(9):762-774. PubMed ID: 32828166
[TBL] [Abstract][Full Text] [Related]
49. Cost-effectiveness of varenicline for smoking cessation.
Keiding H
Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):215-21. PubMed ID: 19527093
[TBL] [Abstract][Full Text] [Related]
50. A cost-effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease.
Lock K; Wilson K; Murphy D; Riesco JA
Expert Opin Pharmacother; 2011 Dec; 12(17):2613-26. PubMed ID: 22017336
[TBL] [Abstract][Full Text] [Related]
51. Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial.
Ebbert JO; Hughes JR; West RJ; Rennard SI; Russ C; McRae TD; Treadow J; Yu CR; Dutro MP; Park PW
JAMA; 2015 Feb; 313(7):687-94. PubMed ID: 25688780
[TBL] [Abstract][Full Text] [Related]
52. Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers.
Howard P; Knight C; Boler A; Baker C
Pharmacoeconomics; 2008; 26(6):497-511. PubMed ID: 18489200
[TBL] [Abstract][Full Text] [Related]
53. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up.
Nides M; Oncken C; Gonzales D; Rennard S; Watsky EJ; Anziano R; Reeves KR
Arch Intern Med; 2006 Aug 14-28; 166(15):1561-8. PubMed ID: 16908788
[TBL] [Abstract][Full Text] [Related]
54. Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece.
Athanasakis K; Igoumenidis M; Karampli E; Vitsou E; Sykara G; Kyriopoulos J
Clin Ther; 2012 Aug; 34(8):1803-14. PubMed ID: 22818870
[TBL] [Abstract][Full Text] [Related]
55. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial.
Tashkin DP; Rennard S; Hays JT; Ma W; Lawrence D; Lee TC
Chest; 2011 Mar; 139(3):591-599. PubMed ID: 20864613
[TBL] [Abstract][Full Text] [Related]
56. Cytisine versus varenicline for smoking cessation in New Zealand indigenous Māori: a randomized controlled trial.
Walker N; Smith B; Barnes J; Verbiest M; Parag V; Pokhrel S; Wharakura MK; Lees T; Cubillos Gutierrez H; Jones B; Bullen C
Addiction; 2021 Oct; 116(10):2847-2858. PubMed ID: 33761149
[TBL] [Abstract][Full Text] [Related]
57. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.
Gonzales D; Rennard SI; Nides M; Oncken C; Azoulay S; Billing CB; Watsky EJ; Gong J; Williams KE; Reeves KR;
JAMA; 2006 Jul; 296(1):47-55. PubMed ID: 16820546
[TBL] [Abstract][Full Text] [Related]
58. Effects of varenicline in adult smokers: a multinational, 24-week, randomized, double-blind, placebo-controlled study.
Bolliger CT; Issa JS; Posadas-Valay R; Safwat T; Abreu P; Correia EA; Park PW; Chopra P
Clin Ther; 2011 Apr; 33(4):465-77. PubMed ID: 21635992
[TBL] [Abstract][Full Text] [Related]
59. Cytisine as a smoking cessation aid: Preliminary observations with a modified therapeutic scheme in real life.
Pozzi P; Boffi R; Veronese C; Trussardo S; Valsecchi C; Sabia F; Pastorino U; Apolone G; Cardani E; Tarantini F; Munarini E
Tumori; 2024 Apr; 110(2):124-131. PubMed ID: 38149659
[TBL] [Abstract][Full Text] [Related]
60. Varenicline: a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist approved for smoking cessation.
Lam S; Patel PN
Cardiol Rev; 2007; 15(3):154-61. PubMed ID: 17438382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
